THURSDAY, October 14, 2021 (HealthDay News) – For children and adolescents with type 1 diabetes, hybrid closed-loop therapy (HCL) improves blood sugar control and quality of life, according to a study published online on October 11 in JAMA Pediatrics.
Mary B. Abraham, Ph.D., University of Western Australia, and colleagues examined the percentage of time spent in target blood sugar range using HCL compared to current conventional therapies in a trial six-month randomized clinic including children and adolescents with type 1 diabetes. Data were included for 135 patients: 68 randomly assigned to the control group and 67 to the HCL group.
The researchers found that in the intention-to-treat analyzes, there was an increase in time in the range (in a glucose range of 70 to 180 mg / dL) from baseline at the end of the study, from 53.1 to 62.5% in the HCL group and from 54.6 to 56.1 percent in the control group (adjusted mean difference, 6.7 percent). The time spent by patients in a hypoglycemic range (
Several authors have revealed links with the pharmaceutical and medical device industries; in-kind support was provided by Medtronic through the provision of insulin pumps, sensors and transmitters for the study, and Roche Diabetes Care provided the blood glucose monitors for the study.
Summary / Full Text (subscription or payment may be required)
Copyright © 2021 Health Day. All rights reserved.